Cargando…

560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections

BACKGROUND: The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is seriously impacting health and economies all over the world. With more than 8 million diagnosed cases and close to 450.000 deaths worldwide by mid-June 2020, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reig, Núria, Shin, Dong-Hae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777092/ http://dx.doi.org/10.1093/ofid/ofaa439.754

Ejemplares similares

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

1243. Eravacycline in Bacteremia: A Case Series
por: Andrade, Justin A, et al.
Publicado: (2021)

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors
por: Jo, Seri, et al.
Publicado: (2022)

1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections
por: Carr, Amy, et al.
Publicado: (2020)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

560. Evaluation of Optimal Methylprednisolone Dose in Patients with Covid 19
por: Ferreiro, Jose Luis Lamas, et al.
Publicado: (2021)

1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus
por: Rausch, Ethan, et al.
Publicado: (2022)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

2137. Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Lim, Andy, et al.
Publicado: (2023)

486. Characteristics Associated with SARS-CoV-2 Infection in Children
por: Curtis Sudbury, F, et al.
Publicado: (2021)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

301. Detection of Pneumococcal Pneumonia During SARS-CoV-2 Infection
por: Watkins, Anne, et al.
Publicado: (2021)

1586. A Comparative Analysis of In Vitro Susceptibilities of Vancomycin-Resistant Enterococci Against Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline
por: Chua, Mary Francine P, et al.
Publicado: (2020)

503. In vitro Evaluation of Sitagliptin-HIV-1 Trans-activator Transcription Peptide Nano-formula for Antiviral Activity Against SARS-CoV-2: Drug Repurposing Approach
por: Eljaaly, Khalid, et al.
Publicado: (2021)

560. Circulating Pneumocystis jirovecii Genotypes in Central-Eastern Canada
por: Roy, Valerie, et al.
Publicado: (2023)

283. Population-Based Co-infection of Carbapenem-Resistant Organisms and SARS-CoV-2 in Massachusetts
por: Geoghegan, Ashley, et al.
Publicado: (2021)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

554. Clinical Impact of Monoclonal Antibody Therapy with SARS-CoV-2 Infection
por: Mann, Inderjit, et al.
Publicado: (2021)

487. Experience with Remdesivir for Treatment of SARS-CoV-2 in Patients with Liver Cirrhosis
por: Saunders-Hao, Patricia, et al.
Publicado: (2021)

453. Frequency of Symptoms and Asymptomatic SARS-CoV-2 Infection in New Orleans, Louisiana
por: Feehan, Amy K, et al.
Publicado: (2020)

450. Evaluating First Responders for SARS-CoV-2 Infection in Broward County, Florida
por: Eckardt, Paula, et al.
Publicado: (2020)

575. Local Experience of Breakthrough SARS-CoV-2 Infections After Full Vaccination
por: Khan, Ahmed A, et al.
Publicado: (2021)

462. Differences in the Humoral Response to SARS-CoV-2 Infection in Children vs. Adult
por: Mentor, Girlande, et al.
Publicado: (2021)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

513. Viral kinetics of SARS-CoV-2 in patients with COVID-19
por: Kim, Da Young, et al.
Publicado: (2020)

354. SARS-CoV-2 Viral Viability Culture and Sequencing from Immunocompromised Patients with Persistently Positive SARS-CoV-2 PCR Results
por: Sung, Abby, et al.
Publicado: (2021)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021)

New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection
por: Bauso, Luana Vittoria, et al.
Publicado: (2021)

Repurposing large health insurance claims data to estimate genetic and environmental contributions in 560 phenotypes
por: Lakhani, Chirag M, et al.
Publicado: (2019)

358. Sociodemographic and clinical features of children and adolescents with SARS-CoV-2 infection in Nashville, Tennessee
por: Howard, Leigh, et al.
Publicado: (2020)

378. Descriptive Analysis of SARS-CoV-2 Infections Among Health System and University Employees
por: Seidelman, Jessica, et al.
Publicado: (2021)

491. Persistence of SARS-CoV-2 Iinfection in Immunocompromised Children
por: Dolan, Susan, et al.
Publicado: (2021)

380. Environmental Contamination with SARS-CoV-2 in Nursing Homes
por: Mody, Lona, et al.
Publicado: (2021)

539. Impact of Corticosteroids when Combined with Tocilizumab or Remdesivir for the Treatment of Severe SARS-CoV-2
por: Rosati, Michael, et al.
Publicado: (2021)

418. Comparison of the Abbott SARS-CoV-2 IgG and DiaSorin LIASON SARS-CoV-2 S1/S2 IgG Antibody Assays
por: Schaack, Grace A, et al.
Publicado: (2020)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2022)

Drug repurposing for SARS-CoV-2 (COVID-19) treatment
por: Mtewa, Andrew G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8es0o8h9vsh500tpkt1ugpckuv